Press Release: Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

Choose a language:

Globe NewsWire News Distribution Service

Details: Written by Globe NewsWire Press Releases; Category: Globe NewsWire News Distribution Service; Published: 14 July 2026; Created: 14 July 2026; Last Updated: 14 July 2026

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative…

Posted: 2026-07-14 00:35:00

Get Full News Story On GlobeNewsWire Press Release Service

More News From This Category
Press Release: FREELANDER Set for Global Brand Launch in Abu Dhabi on 29 September
Mon, 21 Sep 2026 04:08:06 +0000

FREELANDER 8 brings together premium design, intelligent technology and all-terrain capability to address the evolving mobility needs of Freedom Seekers.

Press Release: Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Mon, 21 Sep 2026 01:08:09 +0000

MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE (“ITM”), a global leader in radioisotope production and radiopharmaceutical development.

Press Release: Banyan Announces $50 Million LIFE Offering and Concurrent $8 Million Private Placement
Sun, 20 Sep 2026 22:08:04 +0000

Not for distribution to United States newswire services or for dissemination in the United States

Press Release: INNVENTURE DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Innventure, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INV
Sun, 20 Sep 2026 19:08:05 +0000

NEW YORK, Sept. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Innventure, Inc. (NASDAQ: INV) between November 17, 2025 and August 13, 2026, both dates inclusive (the “Class Period”), of the important October 27, 2026 lead plaintiff deadline.

Press Release: Bronstein, Gewirtz & Grossman LLC Urges York Space Systems, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Sun, 20 Sep 2026 16:08:08 +0000

New class action for York (YSS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/30/2026

Related Bing News Results
Globe Newswire, World News and Updates | Calgary Sun
Tue, 15 Sep 2026 16:32:00 GMT
Canadian Hearing Services announces the recipients of its 2026-2027 National Scholarship Program, awarding 28 scholarships to Deaf and hard of hearing students pursuing post-secondary education across ...